Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Best Practices for Post-Market Surveillance Processes

Posted on November 13th, 2015 by

Donna Sees, an Information Consultant with PharmIntell Consulting, has been a librarian in the medical field for more than 10 years. In this article, she discusses post-market surveillance processes and best practices for medical device companies.

Learn how PharmIntell Consulting took advantage of QUOSA.

Pharmacovigilance: Rethinking Literature Monitoring and Review

Posted on October 27th, 2015 by

Pharmacovigilance is defined as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems.” Under that umbrella, government agencies in the United States, the European Union and other parts of the world have developed diverse and increasingly complex regulatory requirements. (more…)

EMA’s Medical Literature Monitoring: Shakedown or Shakeup

Posted on October 27th, 2015 by

Although, quite a lot of existing flows have to change and new ones have to be implemented, there are, also, quite a lot of benefits, most of them for EMA, and some, not so obvious, for the MAH’s. Of these last ones, many are found by looking at the information, now made available by EMA, as an information professional in a pharmacovigilance context, as well as a pharmacovigilance analyst in an information rich environment.

Read more about EMA’s Medical Literature Monitoring

 

  1. 1
  2. 15
  3. 16
  4. 17